Orthocell, an Australian regenerative-medicine company, reported a 44% jump in fiscal 2026 revenue to AU$13.2 million, fueled by expanding access for its Remplir product in US hospitals. The company now has 44 Value Analysis Committee (VAC) approvals, opening purchasing pathways at 151 hospitals, with 64 more VACs under review, according to broker Euroz Hartleys.
What Are VAC Approvals and Why Do They Matter?
In the US healthcare system, selling a medical device or product to a hospital isn't just about convincing surgeons. It starts with procurement. A Value Analysis Committee is a hospital panel that evaluates new products for cost, clinical effectiveness, and safety. Getting a VAC sign-off is a critical step—it allows the product to be ordered as "business as usual" without needing special approval each time.
For Orthocell, each VAC approval opens the door to multiple hospitals within a health system. The current 44 approvals have unlocked access to 151 hospitals, meaning Remplir can now be routinely purchased at those facilities. With 64 more VACs under review, the potential for further hospital access is significant.
Remplir's Role in Orthocell's Growth
Remplir is a collagen-based matrix used in tendon repair surgeries, such as for rotator cuff tears or Achilles tendon injuries. It's part of Orthocell's broader portfolio of regenerative medicine products that aim to help the body heal itself. The product has been gaining traction in the US, where the market for orthopedic biologics is growing as the population ages and more people seek active lifestyles.
The revenue growth comes as Orthocell continues to expand its sales team and build relationships with hospital systems. The company's strategy focuses on converting VAC approvals into actual sales, a process that can take months but is now showing results.
What This Means for Investors
For everyday investors, Orthocell's progress is a case study in how medical device companies scale in the US market. The VAC approval process is a key metric to watch because it directly correlates with future revenue potential. Each approval represents a new sales channel that can generate recurring orders.
However, investors should note that VAC approvals don't guarantee immediate sales. Hospitals may take time to adopt a new product, and competition from established players like Smith+Nephew or Arthrex is fierce. Orthocell's ability to convert these approvals into consistent revenue growth will be critical.
The broader market for regenerative medicine is expanding, driven by advances in biotechnology and an aging population. Companies like Orthocell that can navigate the complex US hospital procurement system may benefit from this trend. But the path is not without risks—regulatory changes, reimbursement issues, or slower-than-expected adoption could impact growth.
For context, other healthcare companies have faced similar challenges. For instance, Ryman Healthcare has dealt with slow resales affecting cash flow, highlighting the importance of operational efficiency in healthcare. Meanwhile, PepsiCo's struggles with changing consumer habits show how external factors can disrupt even established markets.
Looking Ahead
Orthocell's next milestones will likely be the outcome of those 64 pending VAC reviews. If approved, they could double the company's hospital access, providing a strong foundation for future revenue growth. The company also continues to invest in clinical data to support Remplir's efficacy, which could help speed up adoption.
For investors tracking Orthocell, the key numbers to watch are VAC approval rates, hospital access counts, and quarterly revenue trends. The company's ability to maintain its growth trajectory will depend on converting its pipeline of approvals into sales while managing costs.
In the broader market, Watches of Switzerland recently showed how US sales can drive growth, while small caps often face volatility. Orthocell's story is a reminder that for small-cap medical device companies, execution on the ground—like VAC approvals—can be more important than broad market trends.
